Novozymes (NZM2) Stock Overview
Produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
NZM2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read more
Novozymes A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 49.74 |
| 52 Week High | DKK 65.38 |
| 52 Week Low | DKK 48.50 |
| Beta | 0.75 |
| 1 Month Change | -1.47% |
| 3 Month Change | -7.37% |
| 1 Year Change | -7.55% |
| 3 Year Change | 10.90% |
| 5 Year Change | -7.31% |
| Change since IPO | 1,073.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| NZM2 | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 0.1% | -5.0% | -3.6% |
| 1Y | -7.5% | -14.6% | 0.7% |
Return vs Industry: NZM2 exceeded the German Chemicals industry which returned -14.6% over the past year.
Return vs Market: NZM2 underperformed the German Market which returned 0.7% over the past year.
Price Volatility
| NZM2 volatility | |
|---|---|
| NZM2 Average Weekly Movement | 3.8% |
| Chemicals Industry Average Movement | 4.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: NZM2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NZM2's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11,098 | Ester Baiget | www.novonesis.com |
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel.
Novozymes A/S Fundamentals Summary
| NZM2 fundamental statistics | |
|---|---|
| Market cap | €23.24b |
| Earnings (TTM) | €583.60m |
| Revenue (TTM) | €4.16b |
Is NZM2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NZM2 income statement (TTM) | |
|---|---|
| Revenue | €4.16b |
| Cost of Revenue | €1.85b |
| Gross Profit | €2.31b |
| Other Expenses | €1.72b |
| Earnings | €583.60m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 05, 2026
| Earnings per share (EPS) | 1.25 |
| Gross Margin | 55.45% |
| Net Profit Margin | 14.04% |
| Debt/Equity Ratio | 25.9% |
How did NZM2 perform over the long term?
See historical performance and comparisonDividends
Does NZM2 pay a reliable dividends?
See NZM2 dividend history and benchmarks| Novozymes dividend dates | |
|---|---|
| Ex Dividend Date | Mar 24 2026 |
| Dividend Pay Date | Mar 26 2026 |
| Days until Ex dividend | 18 days |
| Days until Dividend pay date | 20 days |
Does NZM2 pay a reliable dividends?
See NZM2 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 13:33 |
| End of Day Share Price | 2026/03/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novozymes A/S is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sebastian Satz | Barclays |
| Cezara Lozneanu | Barclays |
| Alexander Sloane | Barclays |